Last reviewed · How we verify

NCT02920515

Multi-site Study of Comprehensive Treatment for Children Precocious Puberty

Completed Phase 4 Last updated 28 September 2016
What this trial tests

Phase 4 trial testing Triptorlin or Leuprorelin in Central Precocious Puberty in 740 participants. Completed in 1 August 2015.

Timeline
1 September 2012
Primary endpoint
1 August 2015
1 August 2015

Quick facts

Lead sponsorRuijin Hospital
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment740
Start date1 September 2012
Primary completion1 August 2015
Estimated completion1 August 2015

Drugs / interventions tested

Conditions studied

Sponsor

Ruijin Hospital

Who can join

Adults 2 to 14, female only, with Central Precocious Puberty. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This is a prospective, multicentric, comparative, non-randomized interventional study in which subjects diagnosed with central precocious puberty (CPP) and early puberty (EP) were treated for 6 months to compare the effect with GnRHa and traditional Chinese medicines.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02920515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing